OmniComm Systems Releases IRTMaster Version 5.2
OmniComm Systems, Inc., an Anju Software Company and strategic software solutions provider to the life sciences industry, has announced its release of IRTMaster Version 5.2, an enhanced product offering to complement their comprehensive eClinical suite. IRTMaster is a fully configurable Interactive Responsive Technology (IRT) system that enables subject screening and randomization, clinical supply management, and investigational product assignment at designated drug dispensing visits. Its unique IRTBuilder workflow allows a single user to implement protocol-specific requirements through a collection of configurable, pre-validated modules without custom programming, dramatically shortening timelines for initial builds and mid-study change requirements.
IRTMaster by itself offers a choice of randomization methodologies (including permuted block, dynamic minimization and Zelen), use of multiple warehouses for managing site supplies, configurable user interface in multiple languages, email notifications and alerts, and streamlined user administration enabling management of multiple studies under a single logon. The system integrates seamlessly with TrialMaster EDC with near-real- time, bi-directional integration, allowing data to pass back and forth, eliminating redundancy in data entry for investigative sites. IRTMaster’s ability to act as a stand-alone system or in conjunction with TrialMaster EDC makes it a desirable solution for customers who require flexibility and scalability in their clinical trial development.
“IRTMaster is specifically designed to reduce the burden of setting up randomization and managing drug supplies within a clinical trial,” said Stephen Johnson, chief revenue officer at OmniComm. “This next generation IRT solution is fully self-service, allowing our clients to either set up randomization and drug shipments on their own, or as a service leveraging our expert clinical analysts. Either way, the configurable and pre-validated modules significantly shorten the time it takes to implement compared to competing IRT solutions.”
IRTMaster joins TrialMaster, TrialOne, AutoEncoder and Acuity as one of OmniComm’s principal offerings available through their fully hosted Software-as-a-Service (SaaS) model or Enterprise Enablement deployment model, and supported by their in-house, round-the-clock customer support team.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
